Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo

OBJECTIVES: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become established in the human population, making the need to develop safe and effective treatments critical. We have developed the small-molecule antiviral ensitrelvir, which targets the 3C-like (3CL) protease of SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuroda, Takayuki, Nobori, Haruaki, Fukao, Keita, Baba, Kaoru, Matsumoto, Kazumi, Yoshida, Shinpei, Tanaka, Yukari, Watari, Ryosuke, Oka, Ryoko, Kasai, Yasuyuki, Inoue, Kae, Kawashima, Sho, Shimba, Alice, Hayasaki-Kajiwara, Yoko, Tanimura, Miki, Zhang, Qianhui, Tachibana, Yuki, Kato, Teruhisa, Shishido, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068418/
https://www.ncbi.nlm.nih.gov/pubmed/36760083
http://dx.doi.org/10.1093/jac/dkad027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068418/
https://www.ncbi.nlm.nih.gov/pubmed/36760083
http://dx.doi.org/10.1093/jac/dkad027

Ejemplares similares